-
Shanghai Yingli Pharmaceutical's PI3Kδ inhibitor Linperlisib in the treatment of relapsed/refractory follicular lymphoma Phase 2 registration clinical results are gratifying
Time of Update: 2021-04-14
Linperlisib's phase 2 clinical trial for the treatment of relapsed/refractory follicular lymphoma has achieved gratifying results, which also indicate this The new PI3Kδ selective inhibitor is expected to bring a new therapy for people suffering from this serious disease, and bring hope to these patients and their families.
-
Innovent's PI3Kδ inhibitor Parsaclisib was approved as a breakthrough therapy drug by CDE for the treatment of relapsed or refractory follicular lymphoma
Time of Update: 2021-04-14
At the 62nd American Annual Meeting of Hematology (ASH) in 2020, Incyte reported the data of a clinical study of Parsaclisib in the treatment of relapsed/refractory follicular lymphoma.
Incyte also plans to conduct trials to evaluate parsaclisib combined with tafasitamab in the treatment of non-Hodgkin's lymphoma (NHL) and chronic myeloid leukemia (CLL).
-
Progress in research on platelet biomimetic formulations for combined tumor therapy
Time of Update: 2021-04-14
Inspired by this, combined with the research experience of vaccine adjuvants and tumor immunity, researcher of the Bioformulation and Biomaterials Team of the State Key Laboratory of Biochemical Engineering Ma Guanghui and Wei Weiyan proposed a new strategy for the use of platelet biomimetic formulations in the combined treatment of tumors with photothermal-immune therapy, and conducted collaborative research with Professor Tian Zhiyuan of the National University of Science and Technology.
-
Highlights of Science Journal on April 2, 2021
Time of Update: 2021-04-14
html" target="_blank">Science: New research reveals that elevated striatal dopamine can lead to hallucinations doi:10.
html" target="_blank">Science: New research reveals increased striatal dopamine can cause hallucinations DOI: 10.
html" target="_blank">Science: New research reveals increased striatal dopamine may lead to hallucinations bioon.
-
Express | Blood test found "King of Cancer", unique early screening test was recognized by FDA as a breakthrough medical device
Time of Update: 2021-04-14
The early screening test developed by Bluestar Genomics is a liquid biopsy designed based on circulating cell-free DNA combined with machine learning.
The liquid biopsy designed by Bluestar Genomics detects early pancreatic cancer by detecting changes in a biomarker called hydroxymethylcytosine (5hmC) on circulating cell-free DNA.
-
Brand-new upgraded structure, the times prefer apatamide!
Time of Update: 2021-04-14
A new generation of non-steroidal AR inhibitor apatamide is an ideal AR inhibitor, with higher AR affinity and good tolerability, and its indications are high-risk NM-CRPC and "all types" mHSPC, more Suitable for early use of diseases.
After upgrading, a new generation of AR inhibitor apatamide has brought good survival benefits for prostate cancer patients.
-
The 62-year-old man's stomach cancer and esophageal cancer are "ridden", which is actually related to this Zhejiangese favorite food
Time of Update: 2021-04-14
Not long ago, it was Professor Teng who performed surgery for him, removed the esophageal tumor, and transposed part of the colon to replace the esophagus with precise sutures, allowing him to eat freely again.
-
J Gastroenterol: Residual HBV DNA and pgRNA in patients with chronic hepatitis B can increase the risk of liver cancer by 2-5 times!
Time of Update: 2021-04-13
0 (Roche diagnosis , lower limit of quantification [LLOQ] 20IU/mL) undetectable HBV DNA (HCC and non-HCC 52 each) Cases [matched age, sex, liver cirrhosis and treatment course]) case-control study.
HBV DNA and pgRNA can be detected to be associated with a 2-year increased risk of HCC (hazard ratio [ HR] 2.
-
Lancet oncol: Pembrolizumab can significantly improve the quality of life of patients with metastatic colorectal cancer with MSI-H or dMMR
Time of Update: 2021-04-13
Compared with chemotherapy, pembrolizumab monotherapy, as the first-line treatment for metastatic colorectal cancer with high microsatellite instability or defective mismatch repair, can significantly prolong the progression-free survival of patientsIn order to further support the efficacy and safety results of the trial, this article reports the analysis results of the HRQOL of the patients in the trial .
-
2021 anti-cancer drug medical insurance price summary and inventory
Time of Update: 2021-04-13
In addition, the first domestically produced third-generation lung cancer targeted drug Ametinib was also included in the medical insurance, and the price was reduced by 64% to 3,520 yuan per box.
-
Int J Radiat Oncol Biol Phys: Whether advanced pancreatic cancer is suitable for radiotherapy and chemotherapy, the neutrophil count has a hint!
Time of Update: 2021-04-13
The "Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma" recently published in Int J Radiat Oncol Biol Phys explored whether the baseline neutrophil count can predict OS in LAPC patients .
-
Eur J Cancer: Simple sentinel lymph node resection is expected to replace pelvic lymph node dissection for early cervical cancer!
Time of Update: 2021-04-13
In summary, in early cervical cancer, compared with SN+PLND, simple SN resection (that is, omission of pelvic lymph node dissection) is related to the decrease in the incidence of early lymphatic vessels, and does not significantly affect the patient's recurrence-free survival rate .
-
JCO: Abexiride combined with Fulvestrant has a good effect on patients with PIK3CA mutation HR+/HER2- advanced breast cancer
Time of Update: 2021-04-13
The results showed that the hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and advanced breast cancer patients with PIK3CA mutations received the combination therapy of abesiride and fulvestrant and were well tolerated.
-
Lancet Respirat Med: The third-generation tyrosine kinase inhibitor Furmonertinib has a promising effect in NSCLC patients with EGFR T790M mutation!
Time of Update: 2021-04-13
Furmonertinib (Furatinib, AST2818) is a three-representative skin growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets sensitized EGFR and EGFR Thr790Met (T790M) mutationsThis study aims to evaluate the efficacy and safety of Furmonertinib in advanced non-small cell lung cancer ( NSCLC ) patients with EGFR T790M mutation .
-
Gastroenterology: Eat less high-sugar foods and sugary drinks during adolescence, or significantly increase the risk of colorectal cancer in adulthood!
Time of Update: 2021-04-13
Recently, researchers from the Harvard School of Public Health in the United States and the Seoul National University School of Medicine in South Korea published a study titled Simple sugar and sugar-sweetened beverage intake during adolescence and risk of colorectal cancer precursors in Gastroenterology , and found that adolescence has a large amount of Intake of high-sugar foods and SSB will significantly increase the risk of conventional adenomas and high-risk adenomas, especially rectal adenomas.
-
Nat Commun: The clinical impact of EGFR T790M mutation in advanced non-small cell lung cancer
Time of Update: 2021-04-13
1038/s41467-021-22057-8">Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers .
1038/s41467-021-22057-8">Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers Leave a message here
-
JNCI: Regular use of aspirin can prevent the risk of metastasis after diagnosis of colorectal cancer
Time of Update: 2021-04-13
References: Jane C Figueiredo, PhD, Eric J Jacobs, PhD, Christina C Newton, MSPH, Mark A Guinter, PhD, William G Cance, MD, Peter T Campbell, PhD, Associations of aspirin and non-aspirin non-steroidal anti -inflammatory drugs with colorectal cancer mortality after diagnosis, JNCI: Journal of the National Cancer Institute , 2021;, djab008, org/10.
-
Lancet Sub-Journal: The magic drug aspirin "re-emerges", can reduce the recurrence of colorectal polyps by more than 60%!
Time of Update: 2021-04-13
Recently, researchers from Kyoto Prefecture Medical University in Japan conducted a trial to determine the effect of low-dose aspirin and mesalazine on the recurrence of colorectal polyps in FAP patients.
-
Kangfang Bio-PD1 monoclonal antibody obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma
Time of Update: 2021-04-13
On March 30, Kangfang Biological announced that the FDA granted Paimrizumab breakthrough therapy qualification for the third-line treatment of metastatic nasopharyngeal carcinoma.
In May 2020, Kangfang Bio-Bio submitted to NMPA a new drug listing application for Paimrizumab to treat relapsed or refractory classic Hodgkin's lymphoma (r/rcHL) after at least second-line system chemotherapy.
-
Nature Sub-Journal | Obesity or smoking, which is more terrible?
Time of Update: 2021-04-13
In summary, 15 years of data in the UK suggest that at present, obesity has surpassed smoking and caused more deaths in middle-aged and elderly people.
